|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-6-1
|
|
pubmed:abstractText |
Somatic mutations in EGFR and K-RAS may predict for sensitivity and resistance to EGFR tyrosine kinase inhibitors (TKIs). Whether EGFR and K-RAS mutations could also predict clinical outcome of non-small cell lung cancer (NSCLC) patients following front-line chemotherapy has not yet been established.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1872-8332
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
110-5
|
|
pubmed:meshHeading |
pubmed-meshheading:19854533-Adult,
pubmed-meshheading:19854533-Aged,
pubmed-meshheading:19854533-Aged, 80 and over,
pubmed-meshheading:19854533-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19854533-Female,
pubmed-meshheading:19854533-Humans,
pubmed-meshheading:19854533-Lung Neoplasms,
pubmed-meshheading:19854533-Male,
pubmed-meshheading:19854533-Middle Aged,
pubmed-meshheading:19854533-Mutation,
pubmed-meshheading:19854533-Prognosis,
pubmed-meshheading:19854533-Proto-Oncogene Proteins,
pubmed-meshheading:19854533-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19854533-Survival Analysis,
pubmed-meshheading:19854533-Treatment Outcome,
pubmed-meshheading:19854533-ras Proteins
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.
|
|
pubmed:affiliation |
Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Greece.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
